February 10, 2018 - By Richard Conner
Analysts expect Fortress Biotech, Inc. (NASDAQ:FBIO) to report $-0.57 EPS on March, 15.They anticipate $0.14 EPS change or 32.56% from last quarter’s $-0.43 EPS. After having $-0.67 EPS previously, Fortress Biotech, Inc.’s analysts see -14.93% EPS growth. The stock increased 1.11% or $0.04 during the last trading session, reaching $3.63. About 187,797 shares traded or 65.84% up from the average. Fortress Biotech, Inc. (NASDAQ:FBIO) has risen 52.16% since February 10, 2017 and is uptrending. It has outperformed by 35.46% the S&P500.
Hotchkis & Wiley Capital Management Llc increased Goldman Sachs Group Inc (GS) stake by 21.02% reported in 2017Q3 SEC filing. Hotchkis & Wiley Capital Management Llc acquired 230,900 shares as Goldman Sachs Group Inc (GS)’s stock declined 13.97%. The Hotchkis & Wiley Capital Management Llc holds 1.33 million shares with $315.27 million value, up from 1.10 million last quarter. Goldman Sachs Group Inc now has $94.04B valuation. The stock increased 1.20% or $2.95 during the last trading session, reaching $249.3. About 5.98M shares traded or 77.12% up from the average. The Goldman Sachs Group, Inc. (NYSE:GS) has risen 39.23% since February 10, 2017 and is uptrending. It has outperformed by 22.53% the S&P500.
Among 2 analysts covering Fortress Biotech (NASDAQ:FBIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fortress Biotech had 7 analyst reports since July 11, 2017 according to SRatingsIntel. The stock of Fortress Biotech, Inc. (NASDAQ:FBIO) has “Buy” rating given on Wednesday, September 27 by H.C. Wainwright. The firm has “Buy” rating given on Tuesday, December 5 by H.C. Wainwright. On Tuesday, January 2 the stock rating was maintained by H.C. Wainwright with “Buy”. The company was maintained on Tuesday, December 12 by H.C. Wainwright. The company was maintained on Thursday, August 10 by H.C. Wainwright. The firm earned “Buy” rating on Tuesday, July 11 by H.C. Wainwright.
Fortress Biotech, Inc., a biopharmaceutical company, engages in dermatology product sales, pharmaceutical, and biotechnology businesses in the United States. The company has market cap of $183.88 million. The firm offers CNDO-109, a lysate that activates donor natural killer cells to treat cancer-related and other conditions; tramadol HCl, an intravenous formulation for moderate to moderately severe post-operative pain; CAEL-101 for AL amyloidosis; and CEVA101, which is in Phase II clinical study for severe traumatic brain injury in pediatric patients and adults. It currently has negative earnings. It also provides novel, non-chemotherapy, and immune-enhanced combination treatments for patients with solid tumor cancers; Uracil Topical Cream that is in Phase II to treat and prevent hand-foot syndrome; candidate CUTX-101, a copper histidinate injection for Menkes disease and related copper transport disorders; and novel agents for rare, neglected, or orphan disorders.
Hotchkis & Wiley Capital Management Llc decreased Mcdermott Intl Inc (NYSE:MDR) stake by 403,907 shares to 7.58 million valued at $55.08M in 2017Q3. It also reduced Enstar Group Limited (NASDAQ:ESGR) stake by 7,892 shares and now owns 531,766 shares. Kosmos Energy Ltd (NYSE:KOS) was reduced too.
Since October 18, 2017, it had 0 insider purchases, and 7 insider sales for $25.18 million activity. 7,393 shares were sold by VINIAR DAVID A, worth $1.81M on Friday, October 20. $2.70 million worth of The Goldman Sachs Group, Inc. (NYSE:GS) was sold by SALAME PABLO J. 21,252 shares were sold by SOLOMON DAVID M, worth $5.77 million. SCHWARTZ HARVEY M sold $6.13M worth of The Goldman Sachs Group, Inc. (NYSE:GS) on Friday, October 20. CHAVEZ R. MARTIN also sold $3.18M worth of The Goldman Sachs Group, Inc. (NYSE:GS) on Wednesday, January 31. The insider GNODDE RICHARD J sold $1.19M.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.